Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Last trade$12.11
Day change-$0.46 (-3.66%)
Day range$11.87 – $12.71
Volume272,231
Market cap$1.63B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.63B
Price / earnings
—
Price / book
1.58×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.33×
Profitability
Earnings per share
-$2.51
Return on assets
-30.07%
Return on equity
-31.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
21.84×
Quick ratio
21.84×
Cash ratio
2.53×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$309.65M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KLRA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Revenue
$0
$0
Cost of revenue
$0
$0
Gross profit
$0
$0
Selling, general and administrative
$21.67M
$20.31M
Research and development
$84.67M
$101.06M
Total operating expenses
$106.34M
$121.37M
Operating income
-$106.34M
-$121.37M
Interest expense
$0
$9.99M
Income before taxes
-$95.67M
-$111.31M
Income taxes
$0
$0
Net income
-$95.67M
-$111.31M
Net income attributable to common shareholders
-$95.67M
-$111.31M
EBITDA
-$106.24M
-$121.27M
Basic earnings per share
-$0.74
-$1.09
Diluted earnings per share
-$0.74
-$1.09
Recent news
Company coverage with links to the original publishers.
The article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.
Hengrui Pharma and Kailera Therapeutics announced clinical trial results for ribupatide, a GLP-1/GIP receptor dual agonist in development as both an oral pill and weekly injection for obesity treatment. Phase 2 oral data showed mean weight loss of up to 12.1% with 38.6% of participants achieving 15% weight loss at 26 weeks, with low gastrointestinal side effects. Phase 1 injection data demonstrated similar safety and efficacy across Asian and non-Asian populations. Both companies plan to advance to Phase 3 trials, with global oral trials potentially starting in H1 2027.
Kailera Therapeutics (KLRA) went public on April 17, 2026, pricing at $16 and opening at $26 per share, positioning itself as a competitor in the obesity treatment market. The company has a promising pipeline of weight-loss drug candidates, including its lead candidate Ribupatide in phase 3 trials. While the GLP-1 market could reach $190 billion by 2035, investing in Kailera remains high-risk as the company has no approved commercial products yet.
Kailera Therapeutics, a spinoff of Hengrui Pharma's weight-loss drug portfolio, surged 63% on its Nasdaq debut, validating the 'NewCo' business model where Chinese drugmakers spin off promising pipelines into standalone companies. The IPO raised $625 million, the largest by a Chinese pharma company using this strategy. Hengrui retains a 9.8% stake now valued at ~$300 million and benefits from milestone payments and royalties.
Kailera Therapeutics, Inc. (NASDAQ: KLRA), a clinical-stage biotechnology company focused on obesity care, announced the successful closing of its IPO on April 20, 2026. The company offered 44.9 million shares at $16.00 per share, including the full exercise of underwriters' option for 5.9 million additional shares, generating gross proceeds of $718.8 million. The offering was led by J.P. Morgan, Jefferies, Leerink Partners, TD Cowen, Evercore ISI, and William Blair.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.